IL6 and hypertensive disorder: Nonsteroidal anti-inflammatory drugs can lead to an increase in BP by promoting sodium retention.609,610 Furthermore, Canakinumab, the anti-IL-1β monoclonal antibody, reduced inflammatory factors including IL-1β, IL-6, hs-CRP in patients with atherosclerotic disease, but it did not reduce the incidence of hypertension nor down-regulated BP at 3, 6, or 12 months.364,611–614 However, study suggested that plasma IL-1β concentration elevated in hypertensive patients, no significant change was observed in its receptors levels.